The total investment of Infarco in the companies of the group, which currently employ 1,100 people, will be more than 200 million Euros over the next five years.
Leer másWith more than 60% of its portfoloio composed of international clients, 3P has active presence in major international markets such as USA, Australia, Mexico, Argentina, France, Norway, Italy, UK, Belg...
Leer másThis past April, 3P Biopharmaceuticals obtained GMP (Good Manufacturing Practices) certification for a manufacturing process of a cellular medication destined for allogeneic therapy treatments.
Leer másDámaso Molero:" Creo que en Latinoamérica habrá negocio en el desarrollo de fármacos biosimilares" Trescientas compañías han participado en el primer foro Biolatam, del sector bio...
Leer más